Weekly Ophthalmic Newsletter

1. Alzheimer's First Signs May Appear in Your Eyes, New Study Finds

Researchers at Cedars-Sinavi?have conducted the most comprehensive in-depth analyses of the protein profiles and the molecular, cellular, and structural effects of Alzheimer’s disease in the human retina and how they correspond with changes in the brain and cognitive function.

The findings of this study are crucial for gaining a better understanding of the complex effects of Alzheimer's on the retina, particularly in the early stages of cognitive impairment.?

Click here to read the full news.

2. New Fish Oil Supplement Offers Hope for Preventing Vision Loss

Researchers have developed a new type of omega-3 fatty acid that has the ability to penetrate the retina of the eye. This new supplement has been shown to effectively ward off age-related macular degeneration (AMD), which is one of the leading causes of blindness.

The study suggests that a new fish oil supplement could hold the key to preventing vision loss caused by diseases such as age-related macular degeneration, Alzheimer's, and diabetes.

Click here to read the full news.

3. FDA-Approved Drug Offers Potential Treatment for Childhood Blindness

The National Institutes of Health?has identified a compound already approved by the FDA that keeps light-sensitive photoreceptors alive in three models of Leber congenital amaurosis type 10 (LCA 10), an inherited retinal ciliopathy disease that often results in severe visual impairment or blindness in early childhood.

Click here to read the full news.

4. Sight Sciences Prevails Over Alcon and Ivantis in Patent Invalidation Attempt

Sight Sciences?reported that it defeated all four patent invalidity challenges filed by?Alcon?and Ivantis in the U.S. Patent and Trademark Office. The patent battle started in September 2021, when Sight Sciences filed a lawsuit in the U.S., accusing Ivantis of infringing several U.S. patents by selling the Hydrus? Microstent. The lawsuit sought monetary damages and injunctive relief.

In August 2022, Sight Sciences amended its complaint to add Alcon Inc., Alcon Vision, LLC, and Alcon Research, LLC as defendants and alleged that they also infringed U.S. Patent No. 11,389,328.

The rejections of Alcon's and Ivantis's petitions are final and cannot be appealed. A jury trial lasting five days has been scheduled to begin on April 8, 2024 in Wilmington, Delaware, to address Sight Sciences' claims of patent infringement against Alcon and Ivantis.

Click here to read the full news.

5. FDA Approves Twice-Daily Dosing of Vuity for Adults with Presbyopia

AbbVie?has announced that the FDA has granted approval for the use of?Vuity (pilocarpine HCl ophthalmic solution) 1.25%?twice a day in adults suffering from presbyopia.

The second dose, consisting of an additional drop in each eye, can be administered 3-6 hours after the initial dose. This approval for twice-daily dosing of Vuity may prolong its effectiveness for up to 9 hours.

Click here to read the full news.

If you want to stay updated with the latest news via e-mail,?click here?to subscribe.